Nat. Rev. Cardiol. doi: /nrcardio

Slides:

Advertisements

Similar presentations

Inhibitory Effects of Ticagrelor Compared to Clopidogrel on Platelet Function in Patients with Acute Coronary Syndromes The PLATO PLATELET Substudy Storey.

Advertisements

Prasugrel vs ticagrelor in acute coronary syndromes

A Pharmacodynamic Evaluation of Switching from Ticagrelor to Prasugrel in Subjects with Stable Coronary Artery Disease: Results of the SWAP-2 Study A Pharmacodynamic.

PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic.

Clinical Trial Results. org Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients with Diabetes Mellitus and Coronary Artery Disease:

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Patients With Poor Responsiveness to Thienopyridine.

Adapted from Angiolillo DJ et al. Am J Cardiol. 2006;97: Individual Response Variability to Dual Antiplatelet Therapy in the Steady State Phase of.

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pharmacodynamic Effects of Switching From Prasugrel.

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Irbesartan, an angiotensin type 1 receptor inhibitor,

Challenges with Drug Administration Optimal Loading Dose and Delivery of P2Y12 Inhibitors: Should the Loading Dose Be Crushed? Dominick J. Angiolillo,

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Crushed Prasugrel Tablets in Patients With STEMI.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impaired Responsiveness to the Platelet P2Y 12 Receptor.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel.

From: Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: Coronary artery disease regression.

Nat. Rev. Cardiol. doi: /nrcardio

Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI

When to Switch and How to Switch

How to Switch from Clopidogrel to Prasugrel or Ticagrelor

Robert A. Guyton, MD The Annals of Thoracic Surgery

Nat. Rev. Cardiol. doi: /nrcardio

Francesco Franchi, MD, Fabiana Rollini, MD, Jose Rivas Rios, MD, Andrea Rivas, MD, Malhar Agarwal, MD, Megha Kureti, MD, Deepa Nagaraju, MD, Mustafa Wali,

Glenn N. Levine et al. JACC 2016;68:

Figure 10 Assessment of myocardial fibrosis

Figure 3 Metabolism pathway of antiplatelet agents

Figure 2 Different manifestations of myocardial ischaemia

Figure 2 Binding properties of P2Y12-receptor inhibitors

Reproduced with permission from Yancy, C. W. et al. 2017

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 BMI and cardiorespiratory fitness levels

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Pharmacodynamic comparison of crushed versus integral

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Precision prescribing

Robert A. Guyton, MD The Annals of Thoracic Surgery

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Three-year survival rates on the basis of body composition

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile.

Figure 2 Imaging of atherosclerotic plaque burden

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cardiovascular risk and disease across the life-course

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Decision tree integrating the assessment,

Figure 2 Global cost of HF per capita in 2012

Figure 1 Milestones in coronary angioplasty

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Platelet receptors and available pharmaceutical options

Cardiology Fellow X Factor: An ACS Case of Therapeutic Challenges

Roberta Rossini et al. JCIN 2018;11:

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Effect of Additional Temporary Glycoprotein IIb-IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment.

Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Presentation transcript:

Nat. Rev. Cardiol. doi:10.1038/nrcardio.2015.113 Figure 7 Pharmacodynamics profile of switching therapy from ticagrelor to prasugrel: results from the SWAP‑2 study Figure 7| Pharmacodynamics profile of switching therapy from ticagrelor to prasugrel: results from the SWAP-2 study.82 Time course of platelet inhibition as measured with P2Y12 reaction units in patients with stable coronary artery disease. The results at time 0 (pre-run-in baseline) are the baseline values obtained when patients were receiving aspirin, before the ticagrelor LD was administered. The second baseline values (pre-randomization baseline) were obtained immediately before the first dose of randomized drug was administered, after the run-in phase was completed. 12 h after the last ticagrelor MD was given, patients were randomly assigned to one of three regimens. Data are presented as mean ± SD. Abbreviations: LD, loading dose; MD, maintenance dose. Modified from Angiolillo, D. J. et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 study (Switching Anti Platelet-2). J. Am. Coll. Cardiol. 63 (15), 1500–1509 © (2014), with permission from Elsevier and the American College of Cardiology. Modified from Angiolillo, D. J. et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP‑2 study (Switching Anti Platelet‑2). J. Am. Coll. Cardiol. 63 (15), 1500–1509 © (2014), with permission from Elsevier and the American College of Cardiology Rollini, F. et al. (2015) Switching P2Y12-receptor inhibitors in patients with coronary artery disease Nat. Rev. Cardiol. doi:10.1038/nrcardio.2015.113